Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Signs National Coverage Agreement With Aetna for Thyroid Tests

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that it has signed a national coverage agreement for its ThyGenX and ThyraMir molecular thyroid tests with Aetna.

The ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier are used to diagnose thyroid nodules with indeterminate cytology. According to Interpace, both tests are now covered by a number of Aetna's plans including its commercial and Medicare Advantage plans. The agreement, however, does not include the payor's Medicaid, auto insurance, or workman's compensation products.

"The agreement with Aetna is another significant reimbursement milestone demonstrating our ability to convert our product coverage approvals with major insurance providers into successful contractual agreements," Interpace President and CEO Jack Stover said in a statement. "Coverage of our thyroid products has continued to increase and improve over the past few quarters and now totals over 250 million covered lives."

In April, the firm announced that its ThyraMir test would be covered by United Healthcare.

Earlier this month, Interpace inked a laboratory services agreement for the tests with the Einstein Medical Center of Philadelphia.